Culmination Bio, a St. George, UT-based company building a disease-agnostic patient data intelligence platform, raised $10M in funding.
The round saw participation from Merck Global Health Innovation Fund (Merck GHI) and Amgen Ventures.
The company intends to use the funds to further develop its Intelligence platform and expand its commercial growth.
Led by Lincoln Nadauld, MD, Ph.D., President and CEO, Culmination Bio maintains exclusive rights to a physical library and cloud-based data lake covering over 40 years of de-identified patient electronic health records and biospecimen data. As the most extensive data lake of its kind, it enables biopharmaceutical companies to gain important insights critical to facilitating diagnostic and therapeutic development.
With a continuously growing library of over five million de-identified patient samples and clinical data spanning decades, biotech and life sciences companies partner with Culmination Bio for rapid access to retrospective patient data and faster access to prospective patients for studies.
FinSMEs
30/11/2023